DG013A

• Description :

  DG013A is a phosphinic acid tripeptide mimetic inhibitor. DG013A displays significantly weak affinity for both ERAP1 (IC50=33 nM) and ERAP2 (IC50=11 nM) . DG013A can be used for the research of autoimmune disease and cancer[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302-H315-H319

• Target :

  Aminopeptidase

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/dg013a.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=P([C@@H](N)CCC1=CC=CC=C1)(O)C[C@@H](CC(C)C)C(N[C@H](C(N)=O)CC2=CNC3=CC=CC=C23)=O

• Molecular Formula :

  C27H37N4O4P

• Molecular Weight :

  512.58

• Precautions :

  P264-P270-P280-P302+P352-P305+P351+P338-P330-P362+P364-P501

• References & Citations :

  [1]Birgit Wilding, et al. Investigating the phosphinic acid tripeptide mimetic DG013A as a tool compound inhibitor of the M1-aminopeptidase ERAP1. Bioorg Med Chem Lett. 2021 Jun 15;42:128050.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2007955-07-7]